行情

TBPH

TBPH

Theravance生物制药
NASDAQ

实时行情|Nasdaq Last Sale

22.93
-0.74
-3.13%
已收盘, 16:11 09/13 EDT
开盘
23.74
昨收
23.67
最高
24.06
最低
22.76
成交量
21.73万
成交额
--
52周最高
35.48
52周最低
15.18
市值
12.99亿
市盈率(TTM)
-5.6563
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TBPH 新闻

  • 本周开庭!苹果拟对抗欧盟140亿美元天价税单
  • 新浪科技.5小时前
  • 沪指震荡微跌 沙特石油设施遇袭、油价一度跳升20%
  • 新浪财经.5小时前
  • 沙特阿美据称仍在推进IPO工作 尽管设施受到重创
  • 新浪财经综合.5小时前
  • 若沙特局势恶化 韩国将考虑释放战略石油储备
  • 新浪财经综合.5小时前

更多

所属板块

制药
-0.54%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

TBPH 简况

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
展开

Webull提供Theravance Biopharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。